Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 9, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

dexamethasone

DRUG

lenalidomide

DRUG

melphalan

Trial Locations (14)

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute at University of Alberta, Edmonton

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

E1C 6Z8

Moncton Hospital, Moncton

B3H 1V7

Nova Scotia Cancer Centre, Halifax

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

P6A 2C4

Algoma District Cancer Program at Sault Area Hospital, Sault Ste. Marie

M5G 2M9

Princess Margaret Hospital, Toronto

M9N 1N8

Humber River Regional Hospital - Weston, Toronto

J4V 2H1

Hopital Charles Lemoyne, Greenfield Park

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

H2W 1S6

McGill Cancer Centre at McGill University, Montreal

S4T 7T1

Allan Blair Cancer Centre at Pasqua Hospital, Regina

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK